Biofarma · Aprovações da FDA · Ação

MTRI Mentari Therapeutics

Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities…

Ativos registrados: MT-001

Calendário de catalisadores

Catalisadores com data de MTRI, incluindo os decididos recentemente.

Nada agendado neste período.

Eventos recentes na fonte

Todos os eventos na fonte de MTRI, mais recentes primeiro.

Fluxo instantâneo — os eventos aparecem assim que são arquivados.
Nível de decisãoRelevanteNotávelMenor
6 de nov. de 2026
12:00
MTRIMentari Therapeutics, Inc.

Mentari Therapeutics reports Q3 2026 financial results post-merger with InMed

This 10-Q exhibit restates Mentari's financial position, operating expenses, and pipeline as of September 30, 2026. It recaps the completed merger with InMed Pharmaceuticals (closed Nov 6, 2026) and notes the anti-PACAP mAb MT-001 and other candidates remain in preclinical/early development with no new regulatory or clinical milestones announced.

OutroSEC 8-K

Pares por valor de mercado

Empresas do mesmo setor com valor de mercado mais próximo de MTRI.